Literature DB >> 6298167

6-Acetylmethylenepenicillanic acid (Ro 15-1903), a potent beta-lactamase inhibitor. I. Inhibition of chromosomally and R-factor-mediated beta-lactamases.

M Arisawa, R L Then.   

Abstract

6-Acetylmethylenepenicillanic acid (Ro 15-1903) was seen to be a powerful inhibitor of various beta-lactamases. Nearly all of the chromosomally and R-factor-mediated beta-lactamases which were studied were inhibited at much lower concentrations than required with clavulanic acid or sulbactam. Ro 15-1903 protected beta-lactamase-labile penicillins and cephalosporins from hydrolysis. The compound itself was stable against hydrolysis and inhibition of beta-lactamase was irreversible.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6298167     DOI: 10.7164/antibiotics.35.1578

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  7 in total

1.  Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase.

Authors:  F Caron; L Gutmann; A Bure; B Pangon; J M Vallois; A Pechinot; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Beta-lactamases in clinical isolates. Spectrum implications of sulbactam/ampicillin.

Authors:  J F Acar; L Gutmann; M D Kitzis
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

Review 4.  Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

Authors:  D M Campoli-Richards; R N Brogden
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

5.  Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.

Authors:  M R Jacobs; S C Aronoff; S Johenning; D M Shlaes; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

6.  Influence of beta-lactamase inhibitors on the potency of their companion drug with organisms possessing class I enzymes.

Authors:  S J Cavalieri; C C Sanders; C New
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  The molecular basis for the mode of action of Beta-lactam antibiotics and mechanisms of resistance.

Authors:  B W Bycroft; R E Shute
Journal:  Pharm Res       Date:  1985-01       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.